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Summary 
Nitric oxide (NO) synthesis during experimental  endotoxemia  has been shown to have both 
deleterious and beneficial effects. In the present study, we analyzed the in vivo production and 
the regulatory role of NO in the shock syndrome induced by staphylococcal enterotoxin B (SEB) 
in mice. First,  we found that intraperitoneal  administration  of 100/xg SEB in BALB/c mice 
induced a massive synthesis of NO as indicated by high serum levels of nitrite (NO2-) and 
nitrate (NO3-) peaking 16 h after SEB injection.  The inhibition of NO2-  and NO3-  release 
in  mice injected  with  anti-tumor necrosis factor  (TNF)  and/or anti-interferon "y (IFN-~/) 
monoclonal antibody (mAb) before SEB challenge revealed that both cytokines were involved 
in SEB-induced NO overproduction.  In vitro experiments indicated that NO synthase (NOS) 
inhibition by N-nitro-t-arginine methyl ester (L-NAME) enhanced IFN-~/and TNF production 
by splenocytes in response to SEB. A similar effect was observed in vivo as treatment of mice 
with L-NAME resulted in increased IFN-3'  and TNF serum levels 24 h  after SEB challenge, 
together with persistent expression of corresponding cytokine mKNA in spleen. The prolonged 
production of inflammatory cytokines in mice receiving L-NAME and SEB was associated with 
a 95%  mortality rate within 96 h, whereas all mice survived injections  of SEB or t-NAME 
alone. Both TNF and IFN-3' were responsible for the lethality induced by SEB in L-NAME-treated 
mice as shown by the protection provided by simultaneous  administration of anti-IFN-~/and 
anti-TNF mAbs. We conclude the SEB induces NO synthesis in vivo and that endogenous NO 
has protective effects in this model of T cell-dependent shock by downregulating IFN-3' and 
TNF production. 
N 
'itric oxide (NO) overproduction is known to be involved 
in the pathogenesis of LPS (endotoxin)-induced arterial 
hypotension. Indeed, nitric oxide synthase (NOS) inhibitors 
were found to increase systemic vascular resistance in ex- 
perimental endotoxemia (1) and in patients with septic shock 
(2). However, the therapeutic benefit of NOS inhibitors  in 
severe sepsis is controversial as these inhibitors were also found 
to promote glomerular thrombosis and liver damage and to 
increase mortality rates in animals injected with LPS (3-5). 
These observations suggest  that vasodilatation  and inhibi- 
tion of platelet  aggregation and adhesion induced by NO 
might be critical to maintain adequate perfusion of  vital organs 
during endotoxemia  (6). 
Whereas the toxicity of LPS from gram-negative bacteria 
is related to macrophage activation  (7),  staphylococcal en- 
terotoxins exert their pathogenic effects by activating T cells 
expressing a given Vfl gene segment on their TCR (8). Thus, 
injection of staphylococcal enterotoxin B (SEB) in BALB/c 
mice induces a shock syndrome due to the release of inflam- 
matory cytokines by Vfl8-positive T  cells (9). The present 
study was undertaken to determine whether NO is produced 
and has a regulatory role in this model of T cell-dependent 
shock. 
Materials and Methods 
Mice.  10-wk-old BALB/c mice purchased from Bantin and 
Kingman Ltd. (Grimston  Aldbrough Hull, UK) were maintained 
in our animal facilities on standard laboratory chow. 
mAbs.  The R46A2 rat anti-mouse IFN-  y IgG1 mAb (10) and 
LO-DNP-2, a control rat IgG1 mAb (kindly provided by Dr. 
H. Bazin, Experimental  Immunology  Unit, Universit6  Catholique 
de Louvain, Belgium) were produced in ascites form. Purified 
TN3 19-12 hamster anti-mouse TNF IgG1 mAb and its isotype 
control MOPC21 (CB1) were generously  provided by Cell Tech 
(Berkshire, UK). 
Nitrite~Nitrate (NO2-/NOj-) Assay.  Serum  samples were as- 
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reduction  of NO3-  into NO2-  by copper-plated cadmium (11). 
Briefly, 50 #1 of each sample was first deproteinized by incubation 
with 200 #1 ZnSO4 (75 raM) and 250 #1 NaOH (55 mM) for 10 
rain at room temperature. After centrifugation  at  1,000 g for 10 
min, 200 #1 of supernatant and 200 #g of activated cadmium were 
mixed together and stirred at room temperature for 1 h. Activated 
cadmium was prepared as follows: 5 g cadmium powder (100% 
mesh; Johnson Matthey, Karlsruhe, Germany) were first plated with 
copper by stirring in 20 ml of 5 mM CuSO4. Excess metallic Cu 
was  removed by extensive washing  with  glycine-NaOH  buffer 
(pH 9.7). Copper-plated cadmium was then dried on filter paper 
and immediately used for the reduction of NOz- to NO2-. Re- 
duced samples were incubated with an equal volume of Griess re- 
agent and absorbance was measured (A450) on a microplate reader 
(Multiscan  MCC/340;  Labsystems, Helsinki,  Finland).  NO2- 
concentrations  were calculated from a reduced NaNO3 standard 
curve ranging from 5 mM to 0.5 #M. The lower limit of detection 
of NO3-  in this  test was 50/zM. 
Determination of Cytokine Levels by ELISA.  Serum samples were 
assayed for TNF by two-site ELISA using the TN3 9-12 mAb and 
rabbit anti-mouse TNF polyclonal Ab kindly provided by Dr. W. 
Buurman (University of Limburg, Maastricht,  The Netherlands) 
(12). IFN-'y was also quantitated by two-site ELISA using the Ft 
and Db-1 rat anti-mouse IFN-3, mAbs, kindly provided by Dr. 
BiUian (Katholieke  Universiteit Leuven, Leuven,  Belgium) and P. H. 
van der Meide (TNO Health Research, Amsterdam, The Nether- 
lands), respectively (13). The lower limits of detection of  TNF and 
IFN-3' were 20 and 2 U/ml, respectively. 
Analysis of TNF-ce and IFN-  T mRNA Expression.  Spleens  were 
removed  2  and  24  h  after  injection  of  SEB  or  SEB  plus 
N-nitro-r-arginine  methyl ester (t -NAME; Sigma Chemical Co., 
St. Louis, MO). Total RNA was extracted using the guanidium 
thiocyanate method. Preparations of cDNA and PCR for TNF-ot 
and IFN-T genes and for hypoxanthine phosphoribosyl transferase 
(HPRT) housekeeping gene were performed using standard proce- 
dures (14). PCR primers used were as follows: TNF-c~  sense primer 
5'-TCTCATCAGTTCTATGGCCC-Y and antisense 5'-GGGAGT- 
AGACAAGGTACAAC-Y; IFN-3r sense primer 5'-GCTCTGAG- 
ACAATGAACGCT-Y and antisense 5'-AAAGAGATAATCTGGC- 
TCTGC-Y; HPRT sense primer 5'-GTTGGATACAGGCCAGA- 
CTTTGTTG-Y and antisense 5'-GATTCAACTTGCGCTCATC- 
TTAGGC-Y. Reactions were incubated in a DNA thermal cycler 
(Perkin-Elmer Celtus, Norwalk, CT) for 29 cycles. PCR products 
were run on a 2% agarose gel and stained with ethidium bromide. 
In Vivo Administration of  SEB and NOS Inhibitor.  First, we mea- 
sured NO2-/NO3-  serum levels at different time points  after a 
single injection of 100/~g i.p. SEB dissolved  in 100/~1 RPMI (Gibco, 
Paisley, UK). In experiments designed to analyze the role of NO 
in vivo, mice received injections of 2 mg i.p. of r-NAME, a com- 
petitive inhibitor of NOS, 30 min before, simultaneously with, 
and 2, 4, and 6 h after SEB injection. This protocol of t-NAME 
administration  was adapted from that of Shultz and Raij (3). To 
determine  the role of TNF and IFN-3' in the induction  of NO 
and in the lethality of mice coinjected with SEB and L-NAME, 
mice were pretreated with 500/zg i.p. of either anti-IFN-3' mAb, 
anti-TNF mAb, or both mAbs, 2 h before SEB challenge. As con- 
trols, mice were injected with the isotypic controls of anti-IFN-3, 
and anti-TNF mAb. Results obtained after injection of the two 
control mAbs were pooled since they did not differ significantly. 
The endotoxin levels of SEB, L-NAME, and mAb preparations were 
<15 pg/ml as determined by a Limulus amoebocyte  lysate  assay  (LAb 
QCI.,1000; Whittaker MA,  Bioproducts,  Walkersville, MD). 
In Vitro Studies.  After lysis of red cells, 5  x  106 spleen cells 
from normal BALB/c mice were cultured in duplicates in 0.5 ml 
complete medium consisting of RPMI 1640 supplemented with 
2% Ultroser (Gibco), 1%o sodium pyruvate, 1%o t-glutamine,  1%o 
nonessential amino acids, penicillin, streptomycin, and 5 x  10 -s M 
2-M. SEB at a concentration of 10 #g/ml was added in experimental 
wells together with increasing concentrations (0.25-2 mg/ml) of 
t-NAME. After 4 d of incubation in 6% CO2 in humidified air, 
supernatants  were  collected and  assayed for TNF  and  IFN-3~ 
production. 
Statistical Analysis.  Statistical comparisons were made using the 
unpaired two-tailed Mann-Whitney test except for lethality data 
which were analyzed by the two-tailed Log-Rank test. 
Results and Discussion 
Systemic Release of  NO after SEB Injection in BALB/c Mice. 
We first established that injection of 100/zg i.p. SEB in BALB/c 
mice induces a massive  production of NO metabolites. In- 
deed, NO2-/NO3-  serum levels rose from 200  4-  40 pM 
(mean  _+  SEM) before SEB injection to  1,876  _+  305 #M 
16 h  later while they were not influenced by injection of 
medium alone (Fig.  1). 
TNF  and  IFN-7  Mediate  SEB-induced  NO  Overproduc- 
tion.  TNF and IFN-3~ are released  after SEB injection (9, 
15) and both cytokines are known to induce NOS (16,  17). 
We therefore studied the respective roles of TNF and IFN-3~ 
in  the  in  vivo production  of NO2-/NO3-  in  SEB-chal- 
lenged mice. For this purpose, mice were pretreated with ei- 
ther anti-TNF, anti-IFN-% or both mAbs 2 h before injec- 
tion of 100  ftg of SEB,  and peak  serum levels of NO2-/ 
NO3-  were determined 16 h  later.  In preliminary experi- 
ments, we ascertained that the injected amounts of anti-IFN-T 
and  anti-TNF  mAb  efficiently neutralized  corresponding 
cytokines in the circulation of SEB-injected mice (data not 
shown). As shown in Fig.  2, anti-TNF mAb pretreatment 
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Figure 1.  Serum  levels  of NO2-/NO3- after a single injection  of 100 
#g i.p. SEB in BALB/c mice (I). Controls (0) received  RPMI medium 
alone. Results are represented as mean _+ SEM of at least five mice for 
each time point. (Hatched area) Detection limit of NO2-/NO3-. 
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Figure  2.  Involvement  of TNF and IFN-y in SEB-induced  NO over- 
production. Mice were treated before  SEB challenge (100/~g i.p.) with 
either  anti-TNF  mAb, anti-IFN-y  mAb, or anti-TNF  plus antMFN-3"  mAbs, 
as described  in Materials and Methods. The control  mAb group included 
five mice injected with LO-DNP-2 rat mAb and five  mice injected  with 
CB1 hamster mAb. NO2-/NO3- peak serum levels  were measured 16 h 
after SEB injection  and are represented as mean _+ SEM of at least five 
mice in each group. (*)p <0.02; (* *)p <0.01, as compared  with mice 
injected with control mAb and SEB. 
reduced by 63% peak serum levels of NO2-/NO3-  (585  • 
64 VS. 1,594  +  213 #M in mice pretreated with control mAb, 
p  <0.02).  Anti-IFN-3,  mAb  pretreatment was  even more 
efficient since it reduced peak NO2-/NO3-  levels to 321  • 
83 #M ~v <0.01 as compared with mice pretreated with con- 
trol mAb). Coinjection of anti-IFN-3, and anti-TNF mAbs 
before  SEB  completely  prevented  the  increase  in 
NO2-/NO3-  levels. These in vivo data are in keeping with 
the in vitro observations indicating that IFN-3, and TNF in- 
teract synergistically to induce NO synthesis by macrophages 
and hepatocytes (18,  19). 
Inhibition of NO Synthesis Enhances IFN-9, and TNF Syn- 
thesis and Induces Lethality in SEB-injected Mice.  After the 
demonstration that IFN-y and TNF were responsible for NO 
overproduction, we aimed to determine whether NO would 
in turn control the synthesis of those cytokines. This ques- 
tion was first addressed in vitro by analyzing the effect of 
t-NAME, a NOS inhibitor, on the secretion of cytokines by 
spleen cells stimulated with SEB. As shown in Fig.  3,  the 
addition of t-NAME enhanced in a dose-dependent manner 
the secretion of TNF and IFN-3' triggered by SEB. As both 
cytokines are known to be produced by T cells in this setting 
(9,  15,  20),  these data confirm and extend recent observa- 
tions made in experimental parasitic diseases demonstrating 
that NOS inhibition enhanced IFN-y production by T cells 
in vitro (21,  22). 
A  similar effect of NOS inhibition was observed in vivo 
by measuring cytokine serum levels in L-NAME-treated mice. 
First, we verified that NO2-/NO3-  serum levels remained 
at basal values after coinjection of SEB and L-NAME (mean 
_+  SEM 16 h after SEB injection: 265  +  55 #M). As shown 
in Table  1,  in vivo inhibition of NOS did not modify the 
peak serum levels of TNF and IFN-% but prolonged the 
period during which these cytokines persist in the circula- 
tion. In parallel, we found that IFN-3' and TNF-o~ mRNA 
expression in spleen 24 h after SEB injection was increased 
in L-NAME-treated mice (Fig. 4). Moreover, L-NAME did 
not modify the disappearance rate of radiolabeled TNF, indi- 
cating that the effect of NOS inhibition on cytokine serum 
levels was not related to impaired cytokine clearance (data 
not shown).  Taken together, these results demonstrate the 
existence of a regulatory loop by which NO  inhibits  the 
production of TNF and IFN-3, which induce its own synthesis. 
The sustained release of TNF and IFN-3' caused by NOS 
inhibition was associated  with an increased toxicity of SEB. 
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Figure 3.  TNF and IFN-y secretion  by spleen 
cells stimulated with SEB in the presence  or ab- 
sence of the NOS inhibitor t-NAME. 5  x  106 
spleen cells  were  incubated  with 10 #g/ml of SEB 
together  with increasing  concentrations  of t-NAME 
(0-2 mg/ml). After 4 d incubation, TNF and 
IFN-q/production  was assayed  by ELISA.  Hatched 
(IFN-'y)  and open  (TNF) columns  represent  means 
of duplicate samples in one representative  experi- 
ment out of two. TNF and IFN-3' levels in the 
absence of SEB (200 and 20 U/ml), respectively) 
were not modified  by t-NAME addition. 
1155  Florquin  et al.  Brief  Definitive Report Table  1.  TNF and IFN-  T  Serum  Levels after SEB Injection in ~-NAME-treated Mice 
TNF  (U/ml)*  IFN-3, (U/ml)* 
Mice injected  with*  90  min  24  h  4  h  24  h 
SEB  110  _+  4  <20  300  +  30  <2 
SEB  plus L-NAME  120  _+  13  90  _+  7S  270  _+  60  42  +  45 
c-NAME  <20  <20  <2  <2 
* Mice were injected with 100 #g SEB alone, 10 mg t-NAME alone, or 100 #g SEB and 10 mg t-NAME, as described in Materials and Methods. 
TNF and IFN-~" serum levels were measured at their peak (90 min for TNF, 4 h for IFN-3') and 24 h after SEB injection. Results were expressed 
as mean  _+ SEM of at least five mice in each group. 
S  p <0.01  as compared with mice injected with SEB alone. 
Figure  4.  IFN-3' and TNF-c~ 
mRNA expression in  spleen of 
mice injected with SEB or SEB 
plus L-NAME. Spleens (two per 
group) were removed 2 and 24 h 
after SEB or SEB plus L-NAME 
administration and analyzed  by re- 
verse PCR for INF-% TNF-cx, 
and  HPRT mRNA expression. 
(Lane 1) Control uninjected mice; 
(Lane 2) 2 h after SEB alone; (lane 
3) 2 h after SEB plus t-NAME; 
(lane 4) 24 h after SEB alone; and 
(lane  5)  24  h  after  SEB  plus 
t-NAME. 
Indeed,  95%  of mice (15  of 16)  coinjected  with  L-NAME 
and SEB died within 96 h after SEB challenge (Fig. 5) whereas 
no lethality occurred in mice injected with SEB alone (n  = 
20)  or L-NAME alone (n  =  20).  To study the involvement 
of IFN-y and TNF in the mortality induced by the combi- 
nation of t-NAME plus SEB, groups of animals were pretreated 
with anti-IFN-y and/or anti-TNF mAbs. As shown in Fig. 
5,  simultaneous neutralization  of IFN-y and TNF dramati- 
cally reduced  the  mortality  induced  by SEB  in  t-NAME- 
injected mice whereas pretreatment with either anti-TNF mAb 
alone or anti-IFN-'y mAb alone merely delayed animal death 
(Fig.  5).  The role of TNF in SEB-induced  shock has previ- 
ously been demonstrated in o-galactosamine-sensitized mice 
(9) and we recently observed that IFN-'y is involved in the 
lethality induced by SEB in mice treated with anti-IL-lO mAb 
(20). The data presented herein indicate that IFN-'y and TNF 
might  act synergistically in mediating  SEB toxicity as they 
do  in  other  models  of inflammation  (23). 
NO  in  SEB-induced  shock  not  only downregulates  the 
production of inflammatory cytokines as shown in this paper 
but might also reduce their pathogenic  effects. As a matter 
of fact, the vasoactive properties of NO  as well as its ability 
to inhibit platelet aggregation and adhesion could be impor- 
tant in counteracting  the prothrombotic properties of TNF 
and IFN-3, (24, 25).  Indeed, we observed lesions of coagula- 
tive necrosis in  the liver of mice coinjected  with  SEB  and 
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Figure  5.  Involvement  of TNF and IFN-'y in the lethality 
.  induced by SEB in L-NAME-treated mice. Mice were injected 
** a  with L-NAME (total dose, 10 mg) and SEB (100 #g) after 
pretreatment with either control mAb (&, n = 54, including 
30 mice injected with LO-DNP-2 mAb and 24 mice injected 
with CB1 mAb), anti-TNF mAb (1L n =  30), anti-IFN-7 
~[  mAb (E3, n = 33), or anti-TNF plus anti-IFN-y mAbs (O, 
n  =  30). Survival was 100% at 96 h in mice receiving SEB 
,  alone or t-NAME alone (0, n  =  20 in each group). (*)/, 
00  <  0.05, (**)p <0.005, and (***) p <0.0005, as compared 
with mice pretreated with control mAb. 
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animals receiving LPS and L-NAME (4). 
We conclude that NO overproduction is a major protec- 
tive mechanism in the T  cell-dependent shock induced by 
SEB and that NOS inhibition might have detrimental conse- 
quences in T  cell-mediated inflammatory disorders by en- 
hancing both the production and the toxicity of inflamma- 
tory cytokines. 
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